The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer

International Journal of Cancer

Volumn 130, Issue 2, 2012, Pages 419-430

  Lin, Kueiyu Joshua ^a,b   Cheung, Winson Y ^a,c   Lai, Jennifer Yi Chun ^a,d   Giovannucci, Edward L ^a,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b JACOBI MEDICAL CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF MICHIGAN   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

colorectal cancer; estrogen; hormone replacement therapy; menopausal hormone therapy; progesterone; progestogen

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; CANCER RISK; CLIMACTERIUM; COLORECTAL CANCER; HORMONAL THERAPY; HUMAN; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION;

COLORECTAL NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE; RISK FACTORS;

EID: 80052155715     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26026     Document Type: Article

References (50)

1. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q,. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009: CD004143.
2. Grodstein F, Newcomb PA, Stampfer MJ,. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-82.
3. Nanda K, Bastian LA, Hasselblad V, Simel DL,. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-8.
4. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299: 1036-45.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
6. Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein F, Heiman JR, Henderson VW, Hodis HN, Karas RH, Lobo RA, Manson JE, Reid RL, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15: 584-602.
7. Cochran WG,. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
8. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
9. Greenland S,. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994; 140: 290-6.
10. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
11. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
12. van Staa TP, Cooper C, Barlow D, Leufkens HG,. Individualizing the risks and benefits of postmenopausal hormone therapy. Menopause 2008; 15: 374-81.
13. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM,. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-9.
14. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708.
15. Rennert G, Rennert HS, Pinchev M, Lavie O, Gruber SB,. Use of hormone replacement therapy and the risk of colorectal cancer. J Clin Oncol 2009; 27: 4542-7.
16. Johnson JR, Lacey JV, Jr., Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood A,. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 196-203.
17. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD,. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007; 67: 7534-9.
18. Jacobs EJ, White E, Weiss NS, Heckbert SR, LaCroix A, Barlow WE,. Hormone replacement therapy and colon cancer among members of a health maintenance organization. Epidemiology 1999; 10: 445-51.
19. Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR,. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 2007; 18: 723-33.
20. Risch HA, Howe GR,. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev 1995; 4: 21-8.
21. Tannen RL, Weiner MG, Xie D, Barnhart K,. A simulation using data from a primary care practice database closely replicated the women's health initiative trial. J Clin Epidemiol 2007; 60: 686-95.
22. Newcomb PA, Storer BE,. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995; 87: 1067-71.
23. Pukkala E, Tulenheimo-Silfvast A, Leminen A,. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 2001; 12: 111-5.
24. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D,. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
25. Prihartono N, Palmer JR, Louik C, Shapiro S, Rosenberg L,. A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 443-7.
26. Tannen RL, Weiner MG, Xie D, Barnhart K,. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007; 22: 1769-77.
27. Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA,. Defining hormone replacement therapy in longitudinal studies: impact on measures of effect. Pharmacoepidemiol Drug Saf 2004; 13: 215-25.
28. Persson I, Yuen J, Bergkvist L, Schairer C,. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-32.
29. Delellis Henderson K, Duan L, Sullivan-Halley J, Ma H, Clarke CA, Neuhausen SL, Templeman C, Bernstein L,. Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol 171: 415-25.
30. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, Gapstur SM,. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 2009; 18: 2835-41.
31. Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H,. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Therap 2009; 86: 416-24.
32. Wu AH, Siegmund KD, Long TI, Cozen W, Wan P, Tseng CC, Shibata D, Laird PW,. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 31: 1060-7.
33. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E,. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004.
34. McMichael AJ, Potter JD,. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980; 65: 1201-7.
35. McKeown-Eyssen G,. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994; 3: 687-95.
36. Everson GT, McKinley C, Kern F, Jr,. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991; 87: 237-46.
37. Lointier P, Wildrick DM, Boman BM,. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992; 12: 1327-30.
38. Hendrickse CW, Jones CE, Donovan IA, Neoptolemos JP, Baker PR,. Oestrogen and progesterone receptors in colorectal cancer and human colonic cancer cell lines. Br J Surg 1993; 80: 636-40.
39. Di Leo A, Messa C, Russo F, Misciagna G, Guerra V, Taveri R, Leo S,. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa. Preliminary results. Dig Dis Sci 1994; 39: 2038-42.
40. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB,. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536-40.
41. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD,. Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 2003; 14: 75-84.
42. Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C, Peris C, Fiorucci GC, Sismondi P,. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993; 7: 251-8.
43. Ituarte EA, Petrini J, Hershman JM,. Acromegaly and colon cancer. Ann Intern Med 1984; 101: 627-8.
44. Stewart AJ, Johnson MD, May FE, Westley BR,. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990; 265: 21172-8.
45. Carothers AM, Hughes SA, Ortega D, Bertagnolli MM,. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 2002; 187: 77-86.
46. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP,. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000; 20: 3102-15.
47. Poutanen M, Isomaa V, Peltoketo H, Vihko R,. Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol 1995; 55: 525-32.
48. Prentice RL, Pettinger M, Beresford SA, Wactawski-Wende J, Hubbell FA, Stefanick ML, Chlebowski RT,. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1531-7.
49. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ,. Receptor profiling and endocrine interactions of tibolone. Steroids 2003; 68: 21-30.
50. Landgren MB, Helmond FA, Engelen S,. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005; 50: 222-30.